This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Big Data Remove Business Development Remove Insulin Related Topics
Botox Generic Pharmaceutical Bacterium RNA Generic Drugs DNA Cosmetics In-Vivo Contract Manufacturing Dermatology More Related Topics >
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Merck’s total global revenue from Lagevrio was $5.68 billion in 2022. billion ($8.72 billion USD) in 2022.

Sales 98
Sales Manufacturing FDA Approval Life Science 98
article thumbnail

The challenges and trends of cell & gene therapies 

Drug Discovery World

SEPTEMBER 6, 2022

This will be driven in a major way through breadth of ongoing research and an increased move to better tolerated, logistically simpler allogeneic platforms, such as the optimized Natural Killer (NK) cell therapies being developed at ONK Therapeutics. Chris Nowers, CEO, ONK Therapeutics. . “ Víctor Cervera-Carrascón, Tilt Bio. .

Gene Therapy 52
Gene Therapy Gene Manufacturing Medicine 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024